Learn More
A new fluorescent sensor 1, based on the naphthalimide chromophore and thioether-rich crown receptor, exhibited dual signaling behaviors for Hg(2+) and Ag(+) in aqueous solution. Upon addition of Hg(2+), the fluorescence intensity enhanced in a linear fashion with a quantum yield increase of about 5-fold. Moreover, with the 1-Hg(2+) complex, Ag(+) was(More)
A glucose-responsive controlled-release system based on the competitive combination between glucose oxidase, glucosamine and glucose has been described, which exhibits perfect controlled release properties and high selectivity for glucose over other monosaccharides. This paved the way for a new generation of stimuli-responsive delivery systems.
A novel long-wavelength fluorescence probe has been developed for the detection of nitroreductase (NTR) and hypoxia. could be activated by NTR at 0.1 μM to release the fluorophore and significant changes in fluorescence emission at 658 nm were observed. This feature makes it advantageous for imaging hypoxic cells with minimal endogenous interference.
4,5-Diamino-1,8-naphthalimide (DNP)-based chemosensor was designed and synthesized. Probe specifically recognized Cu(2+) ions in neutral aqueous solution. The capture of Cu(2+) by the receptor resulted in deprotonation of the secondary amine conjugated to the 1,8-naphthalimide chromophore, so that the electron-donation ability of the "N" atom would be(More)
A novel ratiometric fluorescent probe for oxalic acid was designed and synthesized, based on the zinc-containing [DAQZ@2Zn(2+)] complex. It shows highly selective "on-off" fluorescence changes with a more than 20 nm blue shift in wavelength for oxalic acids in aqueous solution. Moreover, it can fluorescently respond to oxalic acid in living cells.
P90 ribosomal S6 kinase 2 (RSK2), which was shown to be overexpressed in human cancers, is a serine/threonine kinase and a potential target for cancer treatment. RSK2 comprises two terminal kinase domains (NTKD and CTKD) that can be inhibited by binding with different types of inhibitors at the ATP binding sites. In the absence of a crystal structure of(More)
In the course of screening for novel anticancer compounds, B1 [N-(2-(dimethylamino)ethyl)-2-aminothiazonaphthalimide], a novel amonafide analogue, was generated as a new anticancer candidate. In the present study, B1 displayed stronger antitumor effects than amonafide in HL60 cells. We further examined whether B1 overcomes the resistance conferred by Bcl-2,(More)